CCME GLOBAL LIMITED is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| EBITDA (ex other income) | (0) | (0) | (4) | (0) | (1) |
| margin % | — | — | — | — | — |
| Owners' profit | (0) | (0) | (4) | 4 | (1) |
| EPS, as reported (₹) | (0.09) | (0.11) | (2.92) | 2.70 | 0.53 |
| ROE % · ROCE % | (1.3) · (1.3) | (1.6) · (1.6) | (75.5) · (75.5) | 41.1 · 39.7 | (1.8) · (1.8) |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | (0) | (0) | (0) | (0) | 5 |
| Capex | 0 | 0 | 0 | 0 | 0 |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 4 | (0) | (0) | (0) | (0) | (0) | (1) | (0) |
| Net profit | 4 | (0) | (0) | (0) | (0) | (0) | (1) | (0) |
| EPS (₹) | 2.81 | (0.20) | 0.02 | 0.09 | 0.05 | 0.02 | 0.37 | 0.06 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| ANTHEM BIOSCIENCES LTD | 52,995 | 136.9 | 17.42 | 54.7 | 19.5 | 26.6 | — | 42.0 |
| ADVANCED ENZYME TECH LTD | 3,286 | 19.8 | 1.95 | 11.6 | 10.3 | 13.4 | 8.2 | 33.7 |
| CCME GLOBAL LIMITED ◆ | 136 | 60.0 | 3.39 | — | (1.8) | (1.8) | — | — |
| VIVO BIO TECH LTD. | 39 | 4.1 | 0.41 | 4.9 | (1.8) | 3.2 | 0.6 | 31.5 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Sept 2026 · Newspaper publication of 34th AGM notice | compliance | minimal | — | — |
| 5 Sept 2026 · Book closure Sep 23-29, 2026 for 34th AGM on Sep 29 | compliance | minimal | — | — |
| 5 Sept 2026 · 34th AGM notice with major capital actions, preferential issue, share split, acquisitions | board shareholder meetings | medium | — | — |
| 5 Sept 2026 · 34th AGM notice with name change, acquisitions, stock split and fundraising | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Clarification on typo errors in board meeting outcome filing | fund raising | high | — | — |
| 29 Aug 2026 · Board approves preferential issue for UAE acquisitions and 1:10 stock split | fund raising | medium | — | — |
| 29 Aug 2026 · Board approves preferential share issue, acquisitions, and 1:10 stock split | fund raising | medium | — | — |
| 29 Aug 2026 · Board approves preferential issue, UAE acquisitions and 1:10 stock split | fund raising | high | — | — |
| 29 Aug 2026 · Board approves 2 UAE FMCG acquisitions, share swap, 1:10 stock split, office shift to Maharashtra | general | medium | — | — |
| 29 Aug 2026 · Board approves UAE acquisitions via share swap and cash, 1:10 stock split | strategic transactions | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| Shree Ganesh Biotech (India) L |
| 20 |
| 24.5 |
| 0.31 |
| — |
| 0.6 |
| 0.8 |
| — |
| (7.0) |
| GENOMIC VALLEY BIOTECH LIMITED | 10 | 262.5 | 2.45 | — | 0.8 | 1.0 | — | 40.5 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 60.0 | 28.9 | 142 of 175 | 19% |
| P/B | 3.4 | 3.3 | 88 of 169 | 48% |
| ROCE | (1.8) | 10.7 | 163 of 189 | 14% |
| ROE | (1.8) | 9.9 | 156 of 177 | 12% |
| Debt / Equity | 0.0 | 0.1 | 6 of 177 | 76% |
| Profit growth | (123.7) | 30.0 | 151 of 164 | 8% |
| Market cap | 136 | 803 | 129 of 188 | 32% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
